We are live on ! Find out more
OMC

OUP Management Company Portfolio holdings

AUM $44.5M
1-Year Est. Return 55.11%
This Fund
S&P 500
This Quarter Est. Return
-31.4%
1 Year Est. Return
+55.11%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$72.7M
AUM Growth
-$58.7M
Cap. Flow
-$8.77M
Cap. Flow %
-12.08%
Top 10 Hldgs %
94.86%
Holding
16
New
–
Increased
–
Reduced
3
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
IONQ icon
IonQ
IONQ
+$6.67M
2
SERA icon
Sera Prognostics
SERA
+$1.28M
3
EVLV icon
Evolv Technologies
EVLV
+$633K
4
LABP
Landos Biopharma, Inc. Common Stock
LABP
+$195K

Sector Composition

Rank Sector Weight
1 Healthcare 85.9%
2 Technology 8.3%
3 Industrials 5.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNTA
1
DELISTED
Centessa Pharmaceuticals
CNTA
$14.3M 19.69%
2,937,615
– –
PMVP icon
2
PMV Pharmaceuticals
PMVP
$62.9M
$14.1M 19.4%
989,232
– –
JBIO
3
Jade Biosciences
JBIO
$1.33B
$9.44M 12.99%
17,250
– –
DICE
4
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$8.33M 11.46%
536,693
– –
CYT
5
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
$7.4M 10.18%
2,474,572
– –
IONQ icon
6
IonQ
IONQ
$15.1B
$6.03M 8.3%
1,377,597
-941,922
-41% -$6.67M
EVLV icon
7
Evolv Technologies
EVLV
$1.06B
$4.21M 5.79%
1,582,721
-238,145
-13% -$633K
VOR icon
8
Vor Biopharma
VOR
$1.25B
$1.86M 2.56%
18,736
– –
DTIL icon
9
Precision BioSciences
DTIL
$191M
$1.8M 2.47%
37,464
– –
EFTR
10
DELISTED
eFFECTOR Therapeutics, Inc. Common Stock
EFTR
$1.46M 2%
41,028
– –
LABP
11
DELISTED
Landos Biopharma, Inc. Common Stock
LABP
$1.17M 1.62%
161,276
-21,472
-12% -$195K
RNAC icon
12
Cartesian Therapeutics
RNAC
$255M
$1.13M 1.56%
28,751
– –
LENZ
13
LENZ Therapeutics
LENZ
$166M
$1.12M 1.54%
58,044
– –
SPRO icon
14
Spero Therapeutics
SPRO
$73M
$185K 0.25%
249,070
– –
QTTB icon
15
Q32 Bio
QTTB
$483M
$126K 0.17%
3,556
– –
SERA icon
16
Sera Prognostics
SERA
$77.9M
– –
-337,505
Closed -$1.28M

Similar funds

JMF
Johnson Midwest Financial Glidden, Iowa $44.7M AUM 21.66% 1-Year Est. Return
AMC
Avenir Management Company New York $43.8M AUM 101.91% 1-Year Est. Return
MCAV
Meritech Capital Associates VI Palo Alto, California $45.3M AUM 4.6% 1-Year Est. Return
SIP
Scott Investment Partners Henley-On-Thames, United Kingdom $43.5M AUM 17.97% 1-Year Est. Return
KXA
KPCB XIV Associates Menlo Park, California $42.8M AUM 16.52% 1-Year Est. Return
WRCAI
West Rim Capital Associates II Lehi, Utah $46.8M AUM 11.72% 1-Year Est. Return
MAM
Must Asset Management Seoul, South Korea $40.9M AUM 22.53% 1-Year Est. Return
GIA
G2VP I Associates Portola Valley, California $48.2M AUM 37.59% 1-Year Est. Return

OUP Management Company's Q2 2022 Portfolio in Review

As of Q2 2022, OUP Management Company held 16 positions worth $72.7M, down 45% from $131M the previous quarter. Its ten largest holdings account for 95% of the portfolio.

OUP Management Company withdrew a net $8.77M in Q2 2022, closing 1 position and reducing 3 holdings. Its most notable exit was Sera Prognostics, an estimated $1.28M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 74% a quarter earlier, followed by Technology and Industrials.

  • OUP Management Company's biggest Q2 2022 reduction was IonQ, cutting an estimated $6.67M.
  • OUP Management Company fully exited Sera Prognostics in Q2 2022, selling an estimated $1.28M.
  • OUP Management Company's ten largest holdings make up 95% of its $72.7M portfolio in Q2 2022.
  • OUP Management Company opened 0 new positions and closed 1 in Q2 2022.
  • OUP Management Company's portfolio value fell 45% quarter-over-quarter to $72.7M.

Based on OUP Management Company's 13F filing for Q2 2022, filed 19 Jul 2022.